AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01275222
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAD001 was in tablets of 0.5 mg, 1.0 mg, 2.5 mg and 5.0 mg strength and was taken by mouth, once a week or once a day depending upon the treatment group the patient was enrolled into.
Trial: NCT03591471
Drug: Low Molecular Weight Heparin Calcium Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In controlled group,Low Molecular Weight Heparin Calcium Injection are used for both the light and serious type with the dosage of 100u/kg/d by hypodermic injection for 2 weeks
Trial: NCT03591471
Drug: Chinese medicine placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In controlled group,take a potential necessary for patients who come to the hospital of TCM to take traditional Chinese medicine in consideration, we add the traditional Chinese medicine placebo in controlled group.
Trial: NCT03092154
Drug: Lipid-lowering agents (Artovastatin)
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artovastatin 20 mg /day, orally, 12 consecutive weeks.
Trial: NCT01533389
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dosage form : capsule dosage : placebo 4mg\*2 (8mg) frequency and duration : QD, 4weeks
Trial: NCT00995826
Drug: CS-8958
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled CS-8958
Trial: NCT04152382
Drug: Placebo - IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT04152382
Drug: Placebo - SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT04152382
Drug: LY3509754
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT04152382
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT00634894
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule by mouth daily x 12 weeks
Trial: NCT01055171
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg; Single Dose.
Trial: NCT01685281
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets will be similar in appearance (color and size) to the investigational product
Trial: NCT00940225
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03182088
Drug: norepinephrine infusion (0.025 mcg/Kg/min)
RxNorm normalized name: mepivacaine 0.025 MG/ML / norepinephrine 30 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will receive a bolus of 5 mcg norepinephrine followed by norepinephrine bitartrate infusion of (0.05 mcg/Kg/min) equivalent to norepinephrine base of (0.025 mcg/Kg/min)
Trial: NCT03182088
Drug: norepinephrine infusion (0.050 mcg/Kg/min)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will receive a bolus of 5 mcg norepinephrine followed by norepinephrine infusion of (0.1 mcg/Kg/min) equivalent to norepinephrine base of (0.050 mcg/Kg/min)
Trial: NCT03182088
Drug: norepinephrine infusion (0.075 mcg/Kg/min)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will receive a bolus of 5 mcg norepinephrine followed by norepinephrine infusion of (0.15 mcg/Kg/min) equivalent to norepinephrine base of (0.075 mcg/Kg/min).
Trial: NCT01114425
Drug: Truvada®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02562053
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Women will receive oral fluoxetine 20 mg daily.
Trial: NCT02028221
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet daily by mouth X 4 weeks, then 1 tablet twice daily by mouth for the remaining duration of the trial (12 months)
Trial: NCT02562053
Drug: Placebo 1
RxNorm normalized name: placebo 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women will receive oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation
Trial: NCT02562053
Drug: Placebo 2
RxNorm normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women will receive a daily oral placebo similar to fluoxetine
Trial: NCT00122668
Drug: non-nucleoside reverse transcriptase inhibitors
RxNorm normalized name: Non-nucleoside reverse transcriptase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00122668
Drug: nucleoside reverse transcriptase inhibitors
RxNorm normalized name: Non-nucleoside reverse transcriptase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00122668
Drug: protease inhibitor
RxNorm normalized name: Protease inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02407821
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The matching placebo will be up-titrated and down-titrated at the same time intervals as the active medication.
Trial: NCT00352560
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 0 mg, once daily, 30 days.
Trial: NCT02324569
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets
Trial: NCT00479609
Drug: Transdermal testosterone therapy
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: testosterone 1% hydroalcohol gel
Trial: NCT00479609
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel
Trial: NCT03684395
Drug: Standard of care (Warfarin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routinely collected clinical data (secondary data from patients with non-valvular atrial fibrillation in Sweden); no primary data collection
Trial: NCT01092455
Drug: Heparin N reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysis with Citrasate, acid concentrate plus 100% of patient's standard heparin N dose; Dialysis with Citrasate acid concentrate plus 80% of patient's standard heparin N dose; Dialysis with Citrasate acid concentrate plus 66.7% of patient's standard heparin N dose.
Trial: NCT04254471
Drug: AL3810
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mgQD, 7.5mgQD, 10mgQD
Trial: NCT06416241
Drug: EYLEA 2 MG in 0.05 ML Injection
RxNorm normalized name: EYLEA 2 MG in 0.05 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection
Trial: NCT04254471
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00889486
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03375957
Drug: ATx201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two hundred microliters (200 μL) of test article applied to the test site areas of the upper outer arms
Trial: NCT03751488
Drug: LY03010
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Dose of LY03010 at 351 mg or 156 mg or 117mg
Trial: NCT03751488
Drug: Invega Sustenna 156 MG in 1 ML Prefilled Syringe
RxNorm normalized name: Invega Sustenna 156 MG in 1 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Dose at 156mg
Trial: NCT03375957
Drug: ATx201 Placebo Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two hundred microliters (200 μL) of placebo applied to the test site areas of the upper outer arms
Trial: NCT00719134
Drug: placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo pills
Trial: NCT00719134
Drug: placebo pills
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo pills
Trial: NCT00003454
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with Stage IV Breast Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Trial: NCT01592981
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide:250 mg/sq m, oral, days 1, 8 and 15 of each cycle in the experimental arm.~Cyclophosphamide:250 mg/sq m, oral, days 1, 2 and 3 of each cycle in the control arm.
Trial: NCT02073773
Drug: Levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levodopa 100mg with benserazide 25mg will be administered 3 hours prior to the start of the daily PT/OT session to maximize its pharmacokinetic window ie. blood plasma levels in the narrow window during which functional rewiring of neural circuits is thought to occur.~Levodopa at the lowest available dose (100mg P.O qd) has been shown to improve motor function of stroke patients and their corresponding quality of life. The treatment proposed can be incorporated into their daily rehabilitation routine. Early intervention (within 7-21 days of the infarct) raises the chance for neuroplasticity and improved recovery of their motor function in the short and long run. Levodopa has been proven to be safe to be used in stroke patients (Lancet. 2001 Sep 8;358(9284):787-90., Arch Phys Med Rehabil. 2008 Sep;89(9):1633-41.), however, the side effects of this medication may include nausea, unusual tiredness, dizziness, excessive watering of mouth.
Trial: NCT01264497
Drug: TH9507
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 and 2 mg, sc daily for 12 weeks
Trial: NCT03126760
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for subcutaneous injection
Trial: NCT00592384
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily oral dose of placebo ranging from 37.5 mg up to 300 mg
Trial: NCT02433483
Drug: Intrathecal Triples
FDA approved: no
EMA approved: no
PMDA approved: no
Description: given IT.
Trial: NCT03780907
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily of oral tablet formulation to be taken in the morning, one hour before breakfast, with a glass of water.
Trial: NCT01250405
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One sequence receives placebo for 7 days followed by Cinacalcet 30mg/d for 7 days
Trial: NCT02352402
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02648776
Drug: Exposure to sedative-hypnotic drugs
RxNorm normalized name: MedActive Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: These patients will have been prescribed a sedative-hypnotic drug for at least one week prior to enrollment.
Trial: NCT03733002
Drug: AngongNiuhuang pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group will receive AngongNiuhuang pill 1 pill 1 times/day for 5-day.
Trial: NCT03733002
Drug: Placebo of AngongNiuhuang pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group will receive Placebo of AngongNiuhuang pill 1 pill 1 times/day for 5-day.
Trial: NCT00048555
Drug: IDEC-114
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Group 1 - 125 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions Dose Group 2 - 250 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions Dose Group 3 - 375 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions Dose Group 4 - 500 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions
Trial: NCT02153099
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-058 (ENV8058) placebo-matching oral solution
Trial: NCT00828321
Drug: Altace® 10 mg capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 10 mg
Trial: NCT03007524
Drug: High dose Rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg/d qN, at least 6 months
Trial: NCT03007524
Drug: Low dose Rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg/d qN, at least 6 months
Trial: NCT02878018
Drug: Qi-Ji Shen-Kang formula; Zhu-Bai formula; Yu-Shen formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qi-Ji Shen-Kang formula:15g of field thistle,10g of common edelweiss herb,10g of spreading hedyotis herb,10g ofYunnan manyleaf Paris rhizome,10g of hairyvein agrimonia herb,10g of the root bark of the tree peony,15g of root of red rooted salvia, and 15g ofmembranous mikvetch root.Zhu-Bai formula:10g of glabrous greenbrier rhizome,5g of Chinese atractylodes rhizome,10g of amur corktree bark,10g of common edelweiss her),10g of field thistle,10g of lalang grass rhizome,10g of garden burnet root,5g of longbract cattail pollen,5g of rehmanniae radix, and 5g of Chinese angelica root.Yu-Shen formula:15g of membranous mikvetch root,10g of heterophylla falsestarwort root,10g of field thistle,10g of cogongrass rhizome,10g of spreading hedyotis herb,10g of root of red rooted salvia,10g of fresh root of rehmannia,10g of Asian puccoon,10g of wormwoodlike motherwort herb,10g of common cockscomb inflorescence,10g of gordon euyale,10g of root bark of the tree peony, and 5g of licorice root.
Trial: NCT04005222
Drug: MELATONIN
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Increased lipid peroxidation associated with ischemia of the anterior segment has been prevented by melatonin supplementation.
Trial: NCT01354886
Drug: FSH-GEX™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose
Trial: NCT01193868
Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01102504
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00673465
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules matching SCH 497079, administered orally, once daily for 4 weeks
Trial: NCT03879564
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSS IV bolus 0.3 ml/kg then drip 0.09 ml/kg/hr
Trial: NCT00808977
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching active and experimental treatments
Trial: NCT03018704
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inactive medication. the doses of placebo were titrated the same as the active intervention.
Trial: NCT04383795
Drug: Antithyroid Drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of antithyroid Drug for 6 months
Trial: NCT01110434
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (daily)
Trial: NCT00495183
Drug: caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: caffeine from 300 to 1200 mg/d or 15 mg/kg/d, divided in 3 doses per day.
Trial: NCT00495183
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04135898
Drug: SIBP-04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3mg/kg, infusion in 90 minutes
Trial: NCT01092104
Drug: TBR-652
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TBR-652 25 mg
Trial: NCT01092104
Drug: TBR-652 Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT01092104
Drug: TBR-652 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TBR-652 50 mg QD for 10 days
Trial: NCT01092104
Drug: TBR-652 75 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TBR-652 75 mg QD for 10 days
Trial: NCT01092104
Drug: TBR-652 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TBR-652 100 mg QD for 10 days
Trial: NCT01092104
Drug: TBR-652 150 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TBR-652 150 mg QD for 10 days
Trial: NCT01709162
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00492037
Drug: YM087 oral
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02601378
Drug: LXS196
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LXS196 as a single agent
Trial: NCT02102815
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSS 50 mL IV slowly push over 5 minutes
Trial: NCT02183311
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00918645
Drug: 41 Ca
RxNorm normalized name: Ca 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral 1.2 microgram dose of 41Ca; the first two recruited study subjects will also receive an oral dose of stable calcium isotope (46Ca) to compare initial kinetics with prior work.
Trial: NCT00865384
Drug: REMERON® 15 mg tablets, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received Organon Inc. formulated products under non-fasting conditions
Trial: NCT04415073
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT00697671
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
Trial: NCT01275209
Drug: HCD122
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02496611
Drug: Weight loss with pharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to the drug intervention group will receive Exenatide extended-release.
Trial: NCT02496611
Drug: Weight loss without pharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to the placebo group will receive a placebo.
Trial: NCT01903837
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets taken once daily
Trial: NCT01804465
Drug: SipT Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive standard of care SipT treatment every two weeks for a total of 3 treatments. The three treatments usually take about 30 days to complete.~SipT treatment is given in three 1 hour infusions. Each SipT treatment is generated from a standard blood cell-collection procedure (called leukapheresis) performed 2-3 days prior to the infusion.
Trial: NCT02393144
Drug: Cervical ripening, labor induction, Dinoprostone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of dinoprostone pessary for cervical ripening and labor induction.
Trial: NCT00620867
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 mg oral tablet three time daily with meals for 6 weeks
Trial: NCT00620867
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg oral capsule once daily with morning meal for 6 weeks
Trial: NCT00540423
Drug: SB-497115-GR 12.5mg matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB-497115-GR 12.5mg matching placebo x1 or 2 tablet once a day
Trial: NCT06626607
Drug: CCB use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative antihypertensive medication includes CCB
Trial: NCT06626607
Drug: non-CCB use
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative antihypertensive medication does not include CCB
Trial: NCT03431961
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice daily for 14 days
Trial: NCT01748773
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive capecitabine 850 mg/m\^2 orally twice daily on Days 1-14 of Cycles 1-3 and on 5 days per week during chemoradiotherapy.
Trial: NCT00276744
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
Trial: NCT02742480
Drug: Acenocoumarol
RxNorm normalized name: acenocoumarol
DrugBank: Acenocoumarol (DB01418)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02771912
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qualitative composition of Propofol lipuro 2% excipients
Trial: NCT02725710
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical looking pill to the 600mg Gabapentin pill administered orally 1-2 hours prior to procedure
Trial: NCT01406080
Drug: Tretinoin
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Apply approximately 1 gram of Tretinoin emollient cream 0.05% every night on the entire face, except near the eye region.
Trial: NCT02448160
Drug: salt-poor Human Albumin solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients implanted with an alfapump will receive intermittent salt-poor human albumin solution
Trial: NCT00719420
Drug: Clarithromycin, Metronidazole, Amoxicillin (+Omeprazole)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg bid, metronidazole 500 mg tid, and amoxicillin 500mg tid with or without omeprazole 20 mg bid for 14 days